Free Trial

Icon (ICLR) Competitors

Icon logo
$150.06 -0.77 (-0.51%)
Closing price 07/3/2025 01:48 PM Eastern
Extended Trading
$150.06 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICLR vs. MEDP, CRL, IQV, TCOM, RDDT, GIB, CPAY, TOST, AER, and GRAB

Should you be buying Icon stock or one of its competitors? The main competitors of Icon include Medpace (MEDP), Charles River Laboratories International (CRL), IQVIA (IQV), Trip.com Group (TCOM), Reddit (RDDT), CGI Group (GIB), Corpay (CPAY), Toast (TOST), Aercap (AER), and Grab (GRAB).

Icon vs. Its Competitors

Icon (NASDAQ:ICLR) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Icon presently has a consensus price target of $213.08, suggesting a potential upside of 42.00%. Medpace has a consensus price target of $344.82, suggesting a potential upside of 7.25%. Given Icon's stronger consensus rating and higher probable upside, research analysts clearly believe Icon is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Icon
0 Sell rating(s)
7 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.60
Medpace
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

95.6% of Icon shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 44.0% of Icon shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Medpace had 5 more articles in the media than Icon. MarketBeat recorded 8 mentions for Medpace and 3 mentions for Icon. Medpace's average media sentiment score of 0.88 beat Icon's score of 0.26 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Icon
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medpace
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Medpace has a net margin of 19.31% compared to Icon's net margin of 9.25%. Medpace's return on equity of 54.36% beat Icon's return on equity.

Company Net Margins Return on Equity Return on Assets
Icon9.25% 11.46% 6.49%
Medpace 19.31%54.36%20.81%

Icon has higher revenue and earnings than Medpace. Icon is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Icon$8.28B1.46$791.47M$9.1816.35
Medpace$2.16B4.28$404.39M$13.1024.54

Icon has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Summary

Medpace beats Icon on 9 of the 17 factors compared between the two stocks.

Get Icon News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ICLR vs. The Competition

MetricIconMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$12.12B$7.31B$5.55B$9.04B
Dividend YieldN/A2.78%5.22%4.00%
P/E Ratio16.3527.9427.6420.24
Price / Sales1.4632.38417.15117.30
Price / Cash7.4922.0136.8958.10
Price / Book1.276.698.035.67
Net Income$791.47M$233.06M$3.18B$249.21M
7 Day Performance3.80%3.33%2.93%3.28%
1 Month Performance7.87%1.79%1.72%3.95%
1 Year Performance-53.22%37.40%34.39%20.98%

Icon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICLR
Icon
4.3684 of 5 stars
$150.06
-0.5%
$213.08
+42.0%
-53.2%$12.12B$8.28B16.3541,900
MEDP
Medpace
4.4545 of 5 stars
$313.86
+1.0%
$344.82
+9.9%
-20.1%$9.02B$2.16B23.965,900
CRL
Charles River Laboratories International
4.042 of 5 stars
$151.64
+1.1%
$171.85
+13.3%
-21.3%$7.45B$4.05B-233.2920,100Analyst Downgrade
IQV
IQVIA
4.9165 of 5 stars
$157.69
+0.1%
$226.32
+43.5%
-21.1%$27.28B$15.41B21.4886,000
TCOM
Trip.com Group
4.9218 of 5 stars
$58.64
-0.1%
$77.25
+31.7%
+18.2%$38.31B$7.30B17.0033,700
RDDT
Reddit
2.3034 of 5 stars
$150.74
+5.4%
$139.57
-7.4%
+115.6%$27.81B$1.30B255.502,233Trending News
Analyst Forecast
Insider Trade
GIB
CGI Group
3.8977 of 5 stars
$104.93
+1.5%
$156.75
+49.4%
+4.7%$23.55B$10.79B19.1190,000Positive News
CPAY
Corpay
3.9322 of 5 stars
$332.07
+1.5%
$401.86
+21.0%
+25.4%$23.41B$3.97B23.2910,500Positive News
TOST
Toast
2.7429 of 5 stars
$44.33
+1.0%
$41.21
-7.0%
+69.9%$22.08B$4.96B192.744,500Positive News
Analyst Downgrade
AER
Aercap
2.5356 of 5 stars
$116.96
-0.2%
$119.25
+2.0%
+23.9%$21.85B$8.06B10.38740Gap Up
GRAB
Grab
1.7957 of 5 stars
$5.03
+2.2%
$5.71
+13.4%
+37.9%$20.26B$2.80B251.639,490Trending News

Related Companies and Tools


This page (NASDAQ:ICLR) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners